[go: up one dir, main page]

DE69922834D1 - Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation - Google Patents

Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation

Info

Publication number
DE69922834D1
DE69922834D1 DE69922834T DE69922834T DE69922834D1 DE 69922834 D1 DE69922834 D1 DE 69922834D1 DE 69922834 T DE69922834 T DE 69922834T DE 69922834 T DE69922834 T DE 69922834T DE 69922834 D1 DE69922834 D1 DE 69922834D1
Authority
DE
Germany
Prior art keywords
hbv
preparation
humanized antibody
antibody specific
surface prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69922834T
Other languages
English (en)
Inventor
Jeong Hong
Jeih Ryu
Hyangsuk Hur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Green Cross Corp
Korea Institute of Science and Technology KIST
Original Assignee
Korea Green Cross Corp
Korea Institute of Science and Technology KIST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Green Cross Corp, Korea Institute of Science and Technology KIST filed Critical Korea Green Cross Corp
Application granted granted Critical
Publication of DE69922834D1 publication Critical patent/DE69922834D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE69922834T 1998-11-19 1999-11-19 Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation Expired - Lifetime DE69922834D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19980049663A KR100345463B1 (ko) 1998-11-19 1998-11-19 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
PCT/KR1999/000699 WO2000031141A1 (en) 1998-11-19 1999-11-19 Humanized antibody specific for surface antigen pre-s1 of hbv and preparation method thereof

Publications (1)

Publication Number Publication Date
DE69922834D1 true DE69922834D1 (de) 2005-01-27

Family

ID=37037248

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69922834T Expired - Lifetime DE69922834D1 (de) 1998-11-19 1999-11-19 Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation

Country Status (8)

Country Link
US (1) US7115723B1 (de)
EP (1) EP1131358B1 (de)
JP (1) JP3552103B2 (de)
KR (1) KR100345463B1 (de)
AT (1) ATE285418T1 (de)
CA (1) CA2351315C (de)
DE (1) DE69922834D1 (de)
WO (1) WO2000031141A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1604997A1 (de) * 1999-02-05 2005-12-14 Therapeutic Human Polyclonals, Inc. Aus nicht-menschlichen transgenen Tieren gewonnene menschliche polyklonale Antikörper
AU2907200A (en) * 1999-02-05 2000-08-25 Jens-Ulrich Bulow Human polyclonal antibodies from genetically engineered animals
JP2004517636A (ja) * 2000-10-02 2004-06-17 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー Ｂ型肝炎ウイルスの表面抗原ｓに対するヒト化抗体及びその製造方法
KR100455902B1 (ko) * 2001-07-18 2004-11-12 주식회사 펩트론 Ｂ형 간염 바이러스 표면단백질 프리에스-1 유래의 펩타이드
KR100708398B1 (ko) * 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
ES2593304T3 (es) 2002-05-02 2016-12-07 Wyeth Holdings Llc Conjugados de transportador derivado de caliqueamicina
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
CN100582781C (zh) * 2006-06-27 2010-01-20 厦门大学 联合检测hbv前s1抗原和核心抗原的方法及诊断试剂盒
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
KR101864693B1 (ko) * 2014-11-27 2018-06-07 진원생명과학 주식회사 B형 간염 바이러스의 preS1에 특이적으로 결합하는 항체 및 이의 용도
KR102558839B1 (ko) 2015-03-25 2023-07-25 아이쥐엠 바이오사이언스 인코포레이티드 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도
EP3978521A1 (de) 2015-05-22 2022-04-06 Huahui Health Ltd. Anti-pre-s1-hbv-antikörper
WO2021013135A1 (en) * 2019-07-20 2021-01-28 Huahui Health Ltd. A method of treating hbv infection by using anti-pre-s1 hbv antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202796D0 (en) 1992-02-11 1992-03-25 Wellcome Found Antiviral antibody

Also Published As

Publication number Publication date
WO2000031141B1 (en) 2000-07-20
KR20000033008A (ko) 2000-06-15
WO2000031141A1 (en) 2000-06-02
CA2351315A1 (en) 2000-06-02
KR100345463B1 (ko) 2003-01-08
ATE285418T1 (de) 2005-01-15
EP1131358B1 (de) 2004-12-22
JP2002531073A (ja) 2002-09-24
US7115723B1 (en) 2006-10-03
CA2351315C (en) 2006-01-24
EP1131358A1 (de) 2001-09-12
JP3552103B2 (ja) 2004-08-11

Similar Documents

Publication Publication Date Title
DE69938054D1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
ATE222928T1 (de) Humanisierte antikörper gegen cd38
ZA95786B (en) Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1 recombinant mage-1 and mage-1 derived immunogeni peptides
NZ596723A (en) Human antibodies that bind human il-12 and methods for producing
DE69922834D1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
MY154009A (en) Anti-alpha v beta 6 antibodies
MX9602971A (es) Anticuerpos humanizados contra la molecula vla-4 de adhesion de leucocitos.
DK0699755T3 (da) Fremgangsmåde til opnåelse af modificerede immunglobuliner med reduceret immunogenicitet af variable domæner i et murint antistof, præparater der indeholder disse
BRPI0413489A (pt) composições polipeptìdicas de ligação a cd20
PT994903E (pt) Metodos e composicoes para glicoproteinas galactosiladas
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
DK0853633T3 (da) Humant monoklonalt antistof imod hepatitis B virus overfladeantigen (HBVsAg)
NZ296564A (en) Method of improving antigenicity of antigens or haptens, fusion with rsv peptides; vaccines, vectors, nucleotides
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
EP1411962A4 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
GB0309126D0 (en) Clostridium difficile focussed antibodies
WO2002060954A8 (en) Materials and methods for treatment of hepatitis c
EP1326895B8 (de) Monoklonale antikörper gegen hepatitis b virus
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
DE69527868D1 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.

Legal Events

Date Code Title Description
8332 No legal effect for de